Related trials
ACCELERATE, 2015 - evacetrapib vs placebo
IMPROVE-IT, 2014 - ezetimibe vs control
dal-OUTCOMES, 2012 - dalcetrapib vs placebo
AIM-HIGH, 2011 - niacin vs placebo (on top statin)
dal-VESSEL, 2011 - dalcetrapib vs placebo
ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)
SHARP, 2010 - ezetimibe+simvastatin vs placebo
SEARCH, 2010 - simvastatin high dose vs simvastatin
ARBITER-HALTS 6, 2010 - ezetimibe vs niacin
DEFINE, 2010 - anacetrapib vs placebo
Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)
ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe
Emmerich, 2009 - etofibrate vs placebo
ARBITER 2, 2009 - niacin vs placebo (on top statin)
SANDS, 2008 - aggressive treatment vs standard teatment
JUPITER, 2008 - rosuvastatin vs placebo
GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo
Tuttle, 2008 - low fat diet vs mediterranean-style diet
RADIANCE 1, 2007 - torcetrapib vs placebo (on top of atorvastatin)
ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)
CORONA, 2007 - rosuvastatin vs placebo
METEOR, 2007 - rosuvastatin vs placebo
Krum, 2007 - rosuvastatin vs placebo
RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)
ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)
See also:
All cardiovascular prevention clinical trials
All clinical trials of HDL increasing drugs
All clinical trials of gemfibrozil
|
|
Treatments
Studied treatment |
gemfibrozil 1200 mg/d
|
Control treatment |
placebo
|
Patients
Patients |
post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L |
Baseline characteristics |
Age (mean), yrs |
60 |
Women (%) |
0% |
Total cholesterol (mmol/l) |
5.2 mmol/L |
Diabetes(%) |
0% |
|
Method and design
Randomized effectives |
197 / 198 (studied vs. control) |
Design |
Parallel groups |
Blinding |
double blind |
Follow-up duration |
32 months |
Geographic area |
Germany |
Primary endpoint |
diameters |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
Coronary event
7 / 197
7 / 198
classic
1,01 [0,36;2,81]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
Coronary event
|
7 / 197 (3,6%) |
7 / 198 (3,5%) |
1,01 |
[0,36;2,81] |
|
12545 |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
12545: Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic VEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Lancet 2010 May 10;:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
total cholesterol (at 1 y) |
4,83 (0,63) |
5,48 (0,68) |
-0,65 |
[-0,779;-0,52] |
HDL (at 1 y) |
0,98 (0,17) |
0,88 (0,15) |
0,10 |
[0,068;0,13] |
LDL |
3,39 (0,56) |
3,83 (0,59) |
-0,44 |
[-0,553;-0,33] |
Absolute risk reduction (for a follow-up of 32 months)
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Coronary event |
3,55% |
3,54% |
0,02%
|
Meta-analysis of all similar trials:
cholesterol lowering intervention in cardiovascular prevention for patients with prior MI or with CHD
cholesterol lowering intervention in cardiovascular prevention for all chronical situations
HDL increasing drugs in cardiovascular prevention for all type of patients
Reference(s)
TrialResults-center ID |
TRC10781
|
Trials register # |
NA
|
-
Frick MH, Syv�nne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kes�niemi YA, Pasternack A, Taskinen MR.
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group..
Circulation 1997;96:2137-43
Pubmed
|
Hubmed
| Fulltext
|